The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 23, 2024

Filed:

Oct. 26, 2018
Applicant:

Medizinische Hochschule Hannover, Hannover, DE;

Inventors:

Richard Taubert, Hannover, DE;

Elmar Jaeckel, Hannover, DE;

Niklas T. Baerlecken, Cologne, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/543 (2006.01); A61B 5/00 (2006.01); G01N 33/564 (2006.01); G01N 33/576 (2006.01); A61K 31/52 (2006.01); A61K 31/573 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5767 (2013.01); A61B 5/41 (2013.01); G01N 33/564 (2013.01); A61K 31/52 (2013.01); A61K 31/573 (2013.01); G01N 2800/52 (2013.01);
Abstract

A method for determining or diagnosing the presence or absence, or the risk of development, or the therapy control of autoimmune hepatitis in a subject is provided. In a method, the presence or absence of antibodies against the huntingtin interacting protein 1 related protein (HIP1R) or against immunoreactive peptides derived therefrom are analyzed, the presence of said antibodies is indicative for the presence, or the risk of development or for therapy control of autoimmune hepatitis of the subject. The use of the HIP1R or an immunoreactive peptide derived therefrom in the diagnosis, the risk assessment or therapy control of hepatitis diseases by determining the presence of antibodies against said HIP1R or immunoreactive peptide derived therefrom, may be helpful for differential diagnosis of autoimmune hepatitis.


Find Patent Forward Citations

Loading…